Aspen acquires remaining rights to AZ anaesthetics
14 September 2017 07:00 BST ASTRAZENECA AND ASPEN ENTER AGREEMENT FOR REMAINING RIGHTS TO ANAESTHETIC MEDICINES Agreement builds on 2016 collaboration on commercialisationrights to anaesthetic medicines in markets outside the US AstraZeneca today announced that it has entered into an agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, under which AGI will now acquire the residual rights to the established anaesthetic medicines comprising of Diprivan, EMLA, Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest. AstraZeneca entered into an